9 completed, 5 terminated. 7 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Terminated 2 |
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 3 | Terminated 2, Completed 1 |
Follow Quark Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery mGFR by iohexol clearance - Cardiac Surgery | Terminated | Quark Pharmaceuticals | 16 | 2020-02-21 | 2021-07-16 | |
| QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery teprasiran, Placebo - Cardiac Surgery | Phase 3 | Terminated | Quark Pharmaceuticals | 1043 | 2018-06-29 | 2021-07-16 |
| QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant QPI-1002, Placebo - Delayed Graft Function | Phase 3 | Completed | Quark Pharmaceuticals | 594 | 2016-03-01 | 2020-05-13 |
| Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg, Sham Injection Procedure - Non Arteritic Anterior Ischemic Optic Neuropathy | Phase 2 / Phase 3 | Terminated | Quark Pharmaceuticals | 732 | 2016-02-24 | 2020-07-20 |
| A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery QPI-1002, Placebo - Acute Kidney Injury | Phase 2 | Completed | Quark Pharmaceuticals | 341 | 2015-12-01 | 2019-01-10 |
| Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG) QPI-1007 Injection, (including placebo) - Glaucoma, Angle-closure, Primary, Acute | Phase 2 | Completed | Quark Pharmaceuticals | 46 | 2013-12-01 | 2017-04-07 |
| PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II) - Choroidal Neovascularization, Diabetic Retinopathy | Phase 2 | Completed | Quark Pharmaceuticals | 258 | 2012-02-01 | 2015-02-23 |
| Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients QPI-1007 at various doses - Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy | Phase 1 | Completed | Quark Pharmaceuticals | 48 | 2010-02-01 | 2013-05-13 |
| Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). 0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655 - Age Related Macular Degeneration | Phase 2 | Completed | Quark Pharmaceuticals | 152 | 2009-11-01 | 2012-10-12 |
| I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation I5NP, Saline - Delayed Graft Function, Other Complication of Kidney Transplant | Phase 1 / Phase 2 | Completed | Quark Pharmaceuticals | 374 | 2008-12-01 | 2014-09-18 |
| Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema Laser Treatment, PF-04523655 high, PF-04523655 middle - Diabetic Retinopathy, Diabetes Complications | Phase 2 | Terminated | Quark Pharmaceuticals | 184 | 2008-06-01 | 2012-10-11 |
| A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004) I5NP, Placebo - Acute Renal Failure, Acute Kidney Injury | Phase 1 | Terminated | Quark Pharmaceuticals | 3 | 2008-05-01 | 2010-11-16 |
| A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery I5NP (a small interfering RNA), placebo - Injury of Kidney, Acute Renal Failure | Phase 1 | Completed | Quark Pharmaceuticals | 16 | 2007-08-01 | 2011-02-23 |
| Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD) PF-04523655 - Age-Related Macular Degeneration | Phase 1 | Completed | Quark Pharmaceuticals | 54 | 2007-02-01 | 2012-10-10 |
Acute Kidney Injury (4) · Choroidal Neovascularization (2) · Delayed Graft Function (2) · Diabetic Retinopathy (2) · Macular Degeneration (2) · Optic Neuropathy, Ischemic (2) · Diabetes Complications (1) · Glaucoma (1) · Glaucoma, Angle-Closure (1) · Optic Atrophy (1) · Optic Atrophy, Hereditary, Leber (1) · Optic Neuritis (1) · Retinal Degeneration (1)
PF-04523655 (3) · Ranibizumab (2) · Laser Therapy (1) · RNA, Small Interfering (1) · Sodium Chloride (1) · salicylhydroxamic acid (1)
United States (14) · Germany (7) · Israel (7) · Canada (4) · Spain (4) · Australia (3) · Belgium (3) · Czechia (3) · France (3) · India (3) · United Kingdom (3) · Austria (2) · Denmark (2) · Italy (2) · Singapore (2)
Martin S. Polinsky, M.D. (2) · Nitsan Halevy, MD (2) · Rabia Ozden, MD (2) · Avner Ingerman, M.D., MSc. (1) · Elizabeth Squiers, M.D. (1) · John Holman, M.D.,Ph.D. (1) · Shai Erlich, Ph.D. (1) · Sharon Klier, M.D. (1)
PMID 34474590, PMID 23074206, PMID 30194931, PMID 33239393, PMID 38689404, PMID 42155674